Talk:Z3220040

---

Questions from Lab 10 article

What is the background to the existing problem / disease condition???

Study Shows Mozobil Induces Mobilization Of Stem Cells But Not Myeloma Tumor Cells

Mozobil- able to mobilise stem cells from bone marros to blood - doesnt increase mobility of tumor cells in melonoma patients

Treatment for tumor patients- chemotherapy with autologous stem cell transplantation

Before chemotherapy- patients stem cells collected and then transplanted back into patient after chemotherapy - 2 million stem cell required adn can occur through multiple collection sessions, which increases the risk of comtaminating the sample with tumour cells. - some patients cannot collected enough sample stem cells

Mozobil and Neupogen (filgrastim) solves the above problem Neupogen increases stem cell production in bone marrow Mozobil increases the mobility of stem cells from marrow to blood

Faculty of Medicine at the University of Utah conducted the use of above drugs- they utilized patients with proven poor stem cell mobilizers and potentially poor stem cell mobilizers Found that the majority of patients could produce 2 million stem cells and had successful transplantations

Safety and efficacy assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assessment of tumor cell mobilization